Genenta Science (NASDAQ:GNTA) & Autolus Therapeutics (NASDAQ:AUTL) Head to Head Review

Genenta Science (NASDAQ:GNTA) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Genenta Science and Autolus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Autolus Therapeutics	N/A	-66.76%	-36.90%

Volatility & Risk

Genenta Science has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Institutional and Insider Ownership

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Genenta Science and Autolus Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A
Autolus Therapeutics	$10.50 million	90.50	-$208.38 million	($1.16)	-3.08

Genenta Science has higher earnings, but lower revenue than Autolus Therapeutics.

Analyst Ratings

This is a summary of recent recommendations for Genenta Science and Autolus Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	0	0	1	0	3.00
Autolus Therapeutics	0	1	4	0	2.80

Genenta Science presently has a consensus target price of $25.00, suggesting a potential upside of 401.00%. Autolus Therapeutics has a consensus target price of $8.70, suggesting a potential upside of 143.70%. Given Genenta Science’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Genenta Science is more favorable than Autolus Therapeutics.

Summary

Genenta Science beats Autolus Therapeutics on 6 of the 10 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.